The Biostatistics Core (BC) provides the statistical design, data management, and computational support for all Pancreatic Cancer SPORE investigators. The BC will support consultation and collaboration on all aspects of study design, database development and quality control, as well as analysis and interpretation of data. The statisticians participating in the Biostatistics Core have been chosen for their broad range of expertise and experience in clinical trials, laboratory experiments, genetics and genomics research, and epidemiology studies. Dr. Graham Colditz and Dr. Esther Lu (formerly named Jingxia Liu) have extensive experience as investigators and statisticians within the comprehensive cancer center setting. For example, Dr. Feng Gao has collaborated with Dr. Wang-Gillam (Clinical Co-Leader on Project 3) on her ongoing randomized controlled clinical trials of chemotherapy for the treatment of pancreatic cancer. They are supported by staff with expertise in monitoring minority accrual, ClinPortal, CaTissue, REDCap and data management/analysis for clinical studies. Collectively, these individuals have affiliations with both the Washington University School of Medicine and the Siteman Cancer Center. Their SPORE collaborations will be based on areas of expertise. The Biostatistics Core members have participated regularly in planning meetings for SPORE projects, and will participate in design of developmental projects and career development projects.
The specific aims of this core are to 1: Provide ready access to statistical expertise and computing consultation to the Pancreatic Cancer SPORE; 2: Provide biostatistical/epidemiological expertise for the planning, analysis and reporting of laboratory experiments, epidemiology studies, and clinical trials and links to the bioinformatics core resources for microarray data and high-throughput genomics data processing as needed; 3: Advise and support SPORE investigators and their data collectors (technicians, nurses, data managers, etc.) in the areas of data form design, data collection, record abstraction, computerization, database designing and management, and data quality control; 4: Provide the scientific computing expertise required to meet the data management and analytical needs of Pancreatic Cancer SPORE investigators, and support interpretation and presentation of data.
The Biostatistics Core provides the statistical and computational support for all pancreas cancer SPORE investigators. The Core will support consultation and collaboration on all aspects of study design, database development and quality control, and analysis, interpretation, and presentation of data.
|Pati, Maria Laura; Niso, Mauro; Spitzer, Dirk et al. (2018) Multifunctional thiosemicarbazones and deconstructed analogues as a strategy to study the involvement of metal chelation, Sigma-2 (?2) receptor and P-gp protein in the cytotoxic action: In vitro and in vivo activity in pancreatic tumors. Eur J Med Chem 144:359-371|
|Brauer, David G; Ohman, Kerri A; Jaques, David P et al. (2018) Surgeon Variation in Intraoperative Supply Cost for Pancreaticoduodenectomy: Is Intraoperative Supply Cost Associated with Outcomes? J Am Coll Surg 226:37-45.e1|
|Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024|
|Nywening, Timothy M; Belt, Brian A; Cullinan, Darren R et al. (2018) Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. Gut 67:1112-1123|
|Brenot, Audrey; Knolhoff, Brett L; DeNardo, David G et al. (2018) SNAIL1 action in tumor cells influences macrophage polarization and metastasis in breast cancer through altered GM-CSF secretion. Oncogenesis 7:32|
|Meyer, Melissa A; Baer, John M; Knolhoff, Brett L et al. (2018) Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Nat Commun 9:1250|
|Meyer, Melissa A; DeNardo, David G (2018) Better Together: B7S1 Checkpoint Blockade Synergizes with anti-PD1. Immunity 48:621-623|
|Jiang, Hongmei; Xu, Mai; Li, Lin et al. (2018) Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models. Mol Cancer Ther 17:2144-2155|
|Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:|
|Zhang, Daoxiang; Li, Lin; Jiang, Hongmei et al. (2018) Tumor-Stroma IL1?-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer. Cancer Res 78:1700-1712|
Showing the most recent 10 out of 25 publications